PubRank

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Clinical Trial ID NCT01721772

PubWeight™ 52.45‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01721772

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2014 10.38
2 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
3 Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013 4.78
4 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
5 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
6 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
7 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
8 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
9 Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013 1.22
10 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
11 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
12 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
13 New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015 1.12
14 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
15 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
16 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
17 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
18 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
19 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
20 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013 0.92
21 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
22 Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol 2013 0.90
23 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
24 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
25 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
26 Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. J Clin Med Res 2015 0.85
27 Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 2016 0.84
28 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
29 Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res 2014 0.81
30 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
31 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
32 PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS One 2016 0.78
33 Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016 0.77
34 Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Ther Adv Med Oncol 2015 0.76
Next 100